Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
Year: 2010
Type: review
Abstract: The human genome is epigenetically organized through a series of modifications to the histone proteins that interact with the DNA. In cancer, many of the proteins that regulate these modifications can be altered in both function and expression. One example of this is the family of histone deacetylases (HDACs), which as their name implies remove acetyl groups from the histone proteins, allowing for more condensed nucleosomal structure. HDACs have increased expression in cancer and are also believed to promote carcinogenesis through the acetylation and interaction with key transcriptional regulators. Given this, small molecule histone deacetylases inhibitors have been identified and developed, which not only inhibit HDACs, but can also lead to growth arrest, differentiation, and/or apoptosis in tumors both in vitro and in vivo. Here, we will discuss some of the recent developments in clinical trials utilizing HDACs inhibitors for the treatment of both hematological malignancies as well as solid tumors.
Source: BioMed Research International
DOI: 10.1155/2011/475641
Authors: Mario Federico, Luigi Bagella
Institutions: Temple University, University of Palermo, University of Sassari
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $2,680
Funder: Fondazione Banco di Sardegna
OpenAlex ID: W2008877479
